Enhanced inotropic response to dobutamine in strength-trained subjects with left ventricular hypertrophy

J Appl Physiol (1985). 2000 Feb;88(2):534-9. doi: 10.1152/jappl.2000.88.2.534.

Abstract

To determine whether strength-trained individuals with physiological concentric left ventricular (LV) hypertrophy exhibit enhanced inotropic responses to catecholamines, we studied 11 bodybuilders, aged 33.0 +/- 2 (SE) yr old, and 10 sedentary healthy subjects, aged 31.3 +/- 2.4 yr old, at baseline and during infusion of incremental doses of dobutamine after atropine. The bodybuilders had larger LV mass, posterior wall and septal wall thicknesses, and wall thickness-to-radius ratio, assessed with two-dimensional echocardiography, than did the sedentary subjects. There was a significant correlation between LV mass and lean body mass irrespective of training status. Baseline LV fractional shortening was similar in the two groups. There was a greater inotropic response to dobutamine in the strength-trained individuals, as evidenced by a steeper slope of the fractional shortening-end-systolic wall stress relationship with a higher y-axis intercept and by a shallower end-systolic wall stress-end systolic diameter relationship without changes in end-diastolic diameter. The heart rate response to dobutamine was attenuated in the strength-trained athletes. There was a significant correlation (r = 0.604, P < 0.05) between the inotropic sensitivity to dobutamine and LV mass normalized for lean body mass in the bodybuilders. The data suggest that concentric LV physiological hypertrophy in the resistance-trained individuals is associated with enhanced inotropic but not chronotropic responses to catecholamines.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adrenergic beta-Agonists / pharmacology*
  • Atropine / pharmacology
  • Blood Pressure / drug effects
  • Body Weight
  • Cardiovascular System / drug effects
  • Cardiovascular System / physiopathology
  • Dobutamine / pharmacology*
  • Dose-Response Relationship, Drug
  • Female
  • Heart Rate / drug effects
  • Heart Ventricles / drug effects
  • Heart Ventricles / pathology
  • Heart Ventricles / physiopathology
  • Humans
  • Hypertrophy, Left Ventricular / physiopathology*
  • Male
  • Muscarinic Antagonists / pharmacology
  • Myocardial Contraction / drug effects*
  • Oxygen Consumption / drug effects
  • Physical Endurance / physiology*
  • Receptors, Muscarinic / drug effects

Substances

  • Adrenergic beta-Agonists
  • Muscarinic Antagonists
  • Receptors, Muscarinic
  • Dobutamine
  • Atropine